Your browser doesn't support javascript.
loading
Pleiotropic Analysis of Lung Cancer and Blood Triglycerides.
Zuber, Verena; Marconett, Crystal N; Shi, Jianxin; Hua, Xing; Wheeler, William; Yang, Chenchen; Song, Lei; Dale, Anders M; Laplana, Marina; Risch, Angela; Witoelar, Aree; Thompson, Wesley K; Schork, Andrew J; Bettella, Francesco; Wang, Yunpeng; Djurovic, Srdjan; Zhou, Beiyun; Borok, Zea; van der Heijden, Henricus F M; de Graaf, Jacqueline; Swinkels, Dorine; Aben, Katja K; McKay, James; Hung, Rayjean J; Bikeböller, Heike; Stevens, Victoria L; Albanes, Demetrius; Caporaso, Neil E; Han, Younghun; Wei, Yongyue; Panadero, Maria Angeles; Mayordomo, Jose I; Christiani, David C; Kiemeney, Lambertus; Andreassen, Ole A; Houlston, Richard; Amos, Christopher I; Chatterjee, Nilanjan; Laird-Offringa, Ite A; Mills, Ian G; Landi, Maria Teresa.
Afiliação
  • Zuber V; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Marconett CN; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Shi J; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Hua X; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Wheeler W; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Yang C; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Song L; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Dale AM; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Laplana M; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Risch A; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Witoelar A; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Thompson WK; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Schork AJ; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Bettella F; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Wang Y; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Djurovic S; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Zhou B; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Borok Z; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • van der Heijden HF; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • de Graaf J; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Swinkels D; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Aben KK; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • McKay J; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Hung RJ; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Bikeböller H; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Stevens VL; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Albanes D; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Caporaso NE; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Han Y; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Wei Y; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Panadero MA; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Mayordomo JI; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Christiani DC; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Kiemeney L; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Andreassen OA; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Houlston R; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Amos CI; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Chatterjee N; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Laird-Offringa IA; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Mills IG; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
  • Landi MT; NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine (VZ, AW, FB, YW, OAA), and Prostate Cancer Research Group, Centre for Molecular Medicine Norway, Nordic EMBL Partnership (VZ, IGM), University of Oslo, Oslo, Norway; Division of Mental Health and Addiction, Oslo Univers
J Natl Cancer Inst ; 108(12)2016 12.
Article em En | MEDLINE | ID: mdl-27565901
ABSTRACT
Epidemiologically related traits may share genetic risk factors, and pleiotropic analysis could identify individual loci associated with these traits. Because of their shared epidemiological associations, we conducted pleiotropic analysis of genome-wide association studies of lung cancer (12 160 lung cancer case patients and 16 838 control subjects) and cardiovascular disease risk factors (blood lipids from 188 577 subjects, type 2 diabetes from 148 821 subjects, body mass index from 123 865 subjects, and smoking phenotypes from 74 053 subjects). We found that 6p22.1 (rs6904596, ZNF184) was associated with both lung cancer (P = 5.50x10(-6)) and blood triglycerides (P = 1.39x10(-5)). We replicated the association in 6097 lung cancer case patients and 204 657 control subjects (P = 2.40 × 10(-4)) and in 71 113 subjects with triglycerides data (P = .01). rs6904596 reached genome-wide significance in lung cancer meta-analysis (odds ratio = 1.15, 95% confidence interval = 1.10 to 1.21 , Pcombined = 5.20x10(-9)). The large sample size provided by the lipid GWAS data and the shared genetic risk factors between the two traits contributed to the uncovering of a hitherto unidentified genetic locus for lung cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Triglicerídeos / Pleiotropia Genética / Neoplasias Pulmonares Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Triglicerídeos / Pleiotropia Genética / Neoplasias Pulmonares Idioma: En Ano de publicação: 2016 Tipo de documento: Article